IAM chart discussion only, page-2427

First 2427 Last

Share
Profile

Follow
oreo83

1 Posts.

05/10/17

13:11

Post #: 27682521
Share

Originally posted by s_hancock ↑

I completely understand what you're saying, and appreciate the insight your experience has provided you. I too have experience, more in the case of running businesses across multiple industries, often from a start-up stage and from a relatively low (or zero) customer base. This has taught me many lessons about growth and early-stage business development.

In this instance, we both know all too well that the options are very much in the money, and unless business conditions degrade on a monumental scale, they'll still be in the money when they're due for expiry on the 31st of Dec. The poor performance to date is largely factored in to the SP already, so it'll take a terrible and unforeseen announcement to drive the heads below the strike price and put them out of the money.

I forget the exact value, but the circa $2M cash raised (assuming all oppies are converted) is enough cash to sustain the business for approx. 4x quarters, assuming that cash burn remains the same ($523k last 4C), and revenues do not increase by a single $. I realise these assumptions are very unlikely, but revenues are much more likely to increase at a higher rate that cash burn at this stage of growth, so technically, the incoming cash should be enough to sustain the current organic growth rates. This even allows for increased expenditure on IP development activities for LiLLY and KLiP during the Dec QTR.

These events, in turn, will stabilise the SP heading in to the end of Dec and start of the Mar QTR.

What happens outside of this organic growth, in terms of acquisition, will hopefully be able to be funded from existing cash reserves and deliver immediate cash flow improvements (unlikely I know, unless management hit an amazing buy-out offer with minimal cash involved with shares/options forming the majority of the transaction), or alternatively, will be funded through another CR - preferably later down the track when the price has stabilised.

All IMHO. We can agree to disagree, no?

Expand

https://www.jobstreet.com.ph/en/job/paraplanner-7405089?fr=21&src=44 with company photos attached

IAM Price at posting: 1.4¢ Sentiment: None Disclosure: Held
19 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

There are more pages in this discussion • 61 more messages in this thread...

First 2427 Last

Add CF1 (ASX) to my watchlist

(20min delay)
Last 2.2¢		Change 0.000(0.00%)		Mkt cap ! $12.58M

Open	High	Low	Value	Volume
2.2¢	2.2¢	2.2¢	$2	91

Buyers (Bids)

No.	Vol.	Price($)
1	491617	2.0¢

Sellers (Offers)

Price($)	Vol.	No.
2.2¢	1916	3

View Market Depth

No.	Vol.	Price($)
1	491617	0.020
1	200000	0.019
3	1434231	0.018
1	1000000	0.017
1	1000000	0.016

Price($)	Vol.	No.
0.022	1916	3
0.023	470043	2
0.024	125000	1
0.026	64744	1
0.028	483161	1

Last trade - 13.05pm 07/10/2024 (20 minute delay)

CF1 (ASX) Chart

IAM chart discussion only, page-2427

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

IAM chart discussion only, page-2427

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News